March 04, 2016 –  On February 25, 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ixekizumab (Taltz), intended for the treatment of plaque psoriasis. Ixekizumab (Taltz) will be available …

Ixekizumab (Taltz) for plaque psoriasis: Positive opinion by the European CHMP Read more »

Tagged with: , , , , , , ,

Atlethe's Foot

January 21, 2015 –  On this day, the U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.  Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an …

The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA Read more »

Tagged with: , , , , , , ,